Metformin failed to meet the primary efficacy threshold for preventing patient-reported post-acute sequelae of SARS-CoV-2 at six months in the large-scale ACTIV-6 randomized trial. However, data indicates a significant reduction in clinician-diagnosed long COVID, providing a critical signal for early outpatient intervention strategies.
The quadruple-blinded, placebo-controlled study enrolled nearly 3,000 adults across 90 U.S. sites between September 2023 and May 2024. Participants with confirmed infection received either immediate-release metformin or placebo for 14 days. The cohort largely possessed prior immunity through vaccination or previous infection, reflecting the current outpatient landscape.
At the 180-day mark, only 2.6% of participants reported lingering symptoms attributed to the virus. While metformin did not achieve the statistical probability required to declare efficacy for self-reported symptoms, it demonstrated a stronger clinical impact elsewhere. The drug reduced the adjusted risk of clinician-diagnosed long COVID by 0.7 percentage points compared to placebo, yielding a risk ratio of 0.50.
Safety profiles remained reassuring throughout the study with no cases of lactic acidosis reported. Although metformin did not clearly prevent subjective symptoms in this low-risk population, the 50% reduction in formal long COVID diagnoses warrants continued evaluation for therapeutic protocols.